Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care

BACKGROUND: Irritable bowel syndrome (IBS) is a common functional bowel disorder that has a considerable impact on patient quality of life and substantial societal and health care resource costs. Current treatments are often ineffective. Tricyclic antidepressants have shown promise in secondary care...

Descripción completa

Detalles Bibliográficos
Autores principales: Alderson, Sarah L., Wright-Hughes, Alexandra, Ford, Alexander C., Farrin, Amanda, Hartley, Suzanne, Fernandez, Catherine, Taylor, Christopher, Ow, Pei Loo, Teasdale, Emma, Howdon, Daniel, Guthrie, Elspeth, Foy, Robbie, Ridd, Matthew J., Bishop, Felicity L., Muir, Delia, Chaddock, Matthew, Herbert, Amy, Cooper, Deborah, Gibbins, Ruth, Newman, Sonia, Cook, Heather, Longo, Roberta, Everitt, Hazel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264306/
https://www.ncbi.nlm.nih.gov/pubmed/35804433
http://dx.doi.org/10.1186/s13063-022-06492-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264306/
https://www.ncbi.nlm.nih.gov/pubmed/35804433
http://dx.doi.org/10.1186/s13063-022-06492-6

Ejemplares similares